2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.
Suzanne Trudel, MSc, MD, associate professor, University of Toronto; clinician scientist, Princess Margaret Cancer Centre, discusses primary results and subgroup analyses from the phase 3 DREAMM-7 trial (NCT04246047) of belantamab mafodotin (Blenrep), bortezomib (Velcade), and dexamethasone (BVd) vs daratumumab (Darzalex), bortezomib and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma.
Related Content: